A BARF1-specific mAb as a new immunotherapeutic tool for the management of EBV-related tumors

Riccardo Turrini, Anna Merlo, Debora Martorelli, Damiana Antonia Faè, Roberta Sommaggio, Isabella Monia Montagner, Vito Barbieri, Oriano Marin, Paola Zanovello, Riccardo Dolcetti, Antonio Rosato

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The use of monoclonal antibodies (mAb) for the diagnosis and treatment of malignancies is acquiring an increasing clinical importance, thanks to their specificity, efficacy and relative easiness of use. However, in the context of Epstein-Barr virus (EBV)-related malignancies, only cancers of B-cell origin can benefit from therapeutic mAb targeting specific B-cell lineage antigens. To overcome this limitation, we generated a new mAb specific for BARF1, an EBV-encoded protein with transforming and immune-modulating properties. BARF1 is expressed as a latent protein in nasopharyngeal (NPC) and gastric carcinoma (GC), and also in neoplastic B cells mainly upon lytic cycle induction, thus representing a potential target for all EBV-related malignancies. Considering that BARF1 is largely but not exclusively secreted, the BARF1 mAb was selected on the basis of its ability to bind a domain of the protein retained at the cell surface of tumor cells. In vitro, the newly generated mAb recognized the target molecule in its native conformation, and was highly effective in mediating both ADCC and CDC against BARF1-positive tumor cells. In vivo, biodistribution analysis in mice engrafted with BARF1-positive and -negative tumor cells confirmed its high specificity for the target. More importantly, the mAb disclosed a relevant antitumor potential in preclinical models of NPC and lymphoma, as evaluated in terms of both reduction of tumor masses and long-term survival. Taken together, these data not only confirm BARF1 as a promising target for immunotherapeutic interventions, but also pave the way for a successful translation of this new mAb to the clinical use.

Original languageEnglish
Article numbere1304338
JournalOncoImmunology
Volume6
Issue number4
DOIs
Publication statusPublished - Apr 3 2017

Fingerprint

Human Herpesvirus 4
Monoclonal Antibodies
Neoplasms
B-Lymphocytes
Antibody-Dependent Cell Cytotoxicity
Cell Lineage
Centers for Disease Control and Prevention (U.S.)
Lymphoma
Stomach
Carcinoma
Antigens
Proteins

Keywords

  • ADCC
  • BARF1
  • CDC
  • Epstein–Barr virus
  • immunotherapy
  • monoclonal antibody

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Cite this

A BARF1-specific mAb as a new immunotherapeutic tool for the management of EBV-related tumors. / Turrini, Riccardo; Merlo, Anna; Martorelli, Debora; Faè, Damiana Antonia; Sommaggio, Roberta; Montagner, Isabella Monia; Barbieri, Vito; Marin, Oriano; Zanovello, Paola; Dolcetti, Riccardo; Rosato, Antonio.

In: OncoImmunology, Vol. 6, No. 4, e1304338, 03.04.2017.

Research output: Contribution to journalArticle

Turrini, Riccardo ; Merlo, Anna ; Martorelli, Debora ; Faè, Damiana Antonia ; Sommaggio, Roberta ; Montagner, Isabella Monia ; Barbieri, Vito ; Marin, Oriano ; Zanovello, Paola ; Dolcetti, Riccardo ; Rosato, Antonio. / A BARF1-specific mAb as a new immunotherapeutic tool for the management of EBV-related tumors. In: OncoImmunology. 2017 ; Vol. 6, No. 4.
@article{3d088a1768f747ba88e4f989844fc7a5,
title = "A BARF1-specific mAb as a new immunotherapeutic tool for the management of EBV-related tumors",
abstract = "The use of monoclonal antibodies (mAb) for the diagnosis and treatment of malignancies is acquiring an increasing clinical importance, thanks to their specificity, efficacy and relative easiness of use. However, in the context of Epstein-Barr virus (EBV)-related malignancies, only cancers of B-cell origin can benefit from therapeutic mAb targeting specific B-cell lineage antigens. To overcome this limitation, we generated a new mAb specific for BARF1, an EBV-encoded protein with transforming and immune-modulating properties. BARF1 is expressed as a latent protein in nasopharyngeal (NPC) and gastric carcinoma (GC), and also in neoplastic B cells mainly upon lytic cycle induction, thus representing a potential target for all EBV-related malignancies. Considering that BARF1 is largely but not exclusively secreted, the BARF1 mAb was selected on the basis of its ability to bind a domain of the protein retained at the cell surface of tumor cells. In vitro, the newly generated mAb recognized the target molecule in its native conformation, and was highly effective in mediating both ADCC and CDC against BARF1-positive tumor cells. In vivo, biodistribution analysis in mice engrafted with BARF1-positive and -negative tumor cells confirmed its high specificity for the target. More importantly, the mAb disclosed a relevant antitumor potential in preclinical models of NPC and lymphoma, as evaluated in terms of both reduction of tumor masses and long-term survival. Taken together, these data not only confirm BARF1 as a promising target for immunotherapeutic interventions, but also pave the way for a successful translation of this new mAb to the clinical use.",
keywords = "ADCC, BARF1, CDC, Epstein–Barr virus, immunotherapy, monoclonal antibody",
author = "Riccardo Turrini and Anna Merlo and Debora Martorelli and Fa{\`e}, {Damiana Antonia} and Roberta Sommaggio and Montagner, {Isabella Monia} and Vito Barbieri and Oriano Marin and Paola Zanovello and Riccardo Dolcetti and Antonio Rosato",
year = "2017",
month = "4",
day = "3",
doi = "10.1080/2162402X.2017.1304338",
language = "English",
volume = "6",
journal = "OncoImmunology",
issn = "2162-4011",
publisher = "Taylor and Francis Inc.",
number = "4",

}

TY - JOUR

T1 - A BARF1-specific mAb as a new immunotherapeutic tool for the management of EBV-related tumors

AU - Turrini, Riccardo

AU - Merlo, Anna

AU - Martorelli, Debora

AU - Faè, Damiana Antonia

AU - Sommaggio, Roberta

AU - Montagner, Isabella Monia

AU - Barbieri, Vito

AU - Marin, Oriano

AU - Zanovello, Paola

AU - Dolcetti, Riccardo

AU - Rosato, Antonio

PY - 2017/4/3

Y1 - 2017/4/3

N2 - The use of monoclonal antibodies (mAb) for the diagnosis and treatment of malignancies is acquiring an increasing clinical importance, thanks to their specificity, efficacy and relative easiness of use. However, in the context of Epstein-Barr virus (EBV)-related malignancies, only cancers of B-cell origin can benefit from therapeutic mAb targeting specific B-cell lineage antigens. To overcome this limitation, we generated a new mAb specific for BARF1, an EBV-encoded protein with transforming and immune-modulating properties. BARF1 is expressed as a latent protein in nasopharyngeal (NPC) and gastric carcinoma (GC), and also in neoplastic B cells mainly upon lytic cycle induction, thus representing a potential target for all EBV-related malignancies. Considering that BARF1 is largely but not exclusively secreted, the BARF1 mAb was selected on the basis of its ability to bind a domain of the protein retained at the cell surface of tumor cells. In vitro, the newly generated mAb recognized the target molecule in its native conformation, and was highly effective in mediating both ADCC and CDC against BARF1-positive tumor cells. In vivo, biodistribution analysis in mice engrafted with BARF1-positive and -negative tumor cells confirmed its high specificity for the target. More importantly, the mAb disclosed a relevant antitumor potential in preclinical models of NPC and lymphoma, as evaluated in terms of both reduction of tumor masses and long-term survival. Taken together, these data not only confirm BARF1 as a promising target for immunotherapeutic interventions, but also pave the way for a successful translation of this new mAb to the clinical use.

AB - The use of monoclonal antibodies (mAb) for the diagnosis and treatment of malignancies is acquiring an increasing clinical importance, thanks to their specificity, efficacy and relative easiness of use. However, in the context of Epstein-Barr virus (EBV)-related malignancies, only cancers of B-cell origin can benefit from therapeutic mAb targeting specific B-cell lineage antigens. To overcome this limitation, we generated a new mAb specific for BARF1, an EBV-encoded protein with transforming and immune-modulating properties. BARF1 is expressed as a latent protein in nasopharyngeal (NPC) and gastric carcinoma (GC), and also in neoplastic B cells mainly upon lytic cycle induction, thus representing a potential target for all EBV-related malignancies. Considering that BARF1 is largely but not exclusively secreted, the BARF1 mAb was selected on the basis of its ability to bind a domain of the protein retained at the cell surface of tumor cells. In vitro, the newly generated mAb recognized the target molecule in its native conformation, and was highly effective in mediating both ADCC and CDC against BARF1-positive tumor cells. In vivo, biodistribution analysis in mice engrafted with BARF1-positive and -negative tumor cells confirmed its high specificity for the target. More importantly, the mAb disclosed a relevant antitumor potential in preclinical models of NPC and lymphoma, as evaluated in terms of both reduction of tumor masses and long-term survival. Taken together, these data not only confirm BARF1 as a promising target for immunotherapeutic interventions, but also pave the way for a successful translation of this new mAb to the clinical use.

KW - ADCC

KW - BARF1

KW - CDC

KW - Epstein–Barr virus

KW - immunotherapy

KW - monoclonal antibody

UR - http://www.scopus.com/inward/record.url?scp=85018323456&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018323456&partnerID=8YFLogxK

U2 - 10.1080/2162402X.2017.1304338

DO - 10.1080/2162402X.2017.1304338

M3 - Article

VL - 6

JO - OncoImmunology

JF - OncoImmunology

SN - 2162-4011

IS - 4

M1 - e1304338

ER -